376 related articles for article (PubMed ID: 15744718)
1. Hepatic and intestinal first-pass effects of oltipraz in rats.
Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG
Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han KS; Lee MG
Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506
[TBL] [Abstract][Full Text] [Related]
3. Hepatic and intestinal first-pass effects of a new hepatoprotective agent, YH439, in rats.
Kim J; Han KS; Lee JW; Lee MG
Res Commun Mol Pathol Pharmacol; 1998 Nov; 102(2):125-36. PubMed ID: 10100504
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects.
Shin HS; Bae SK; Lee MG
Int J Pharm; 2006 Aug; 320(1-2):64-70. PubMed ID: 16730145
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
[TBL] [Abstract][Full Text] [Related]
6. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability.
Yang SH; Lee MG
Int J Pharm; 2007 Mar; 332(1-2):17-23. PubMed ID: 17157458
[TBL] [Abstract][Full Text] [Related]
7. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.
Yang SH; Lee MG
Biopharm Drug Dispos; 2008 Oct; 29(7):414-26. PubMed ID: 18697186
[TBL] [Abstract][Full Text] [Related]
8. Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Lee MH; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Yoo SE; Lee MG
J Pharm Sci; 2003 Jan; 92(1):190-201. PubMed ID: 12486695
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oltipraz after intravenous and oral administration in rats with dehydration for 72 hours.
Bae SK; Lee SJ; Kim JW; Kim YH; Kim SG; Lee MG
Biopharm Drug Dispos; 2005 Mar; 26(2):77-83. PubMed ID: 15617135
[TBL] [Abstract][Full Text] [Related]
10. Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects.
Choi YH; Kim SG; Lee MG
J Pharm Sci; 2006 Nov; 95(11):2543-52. PubMed ID: 16937336
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interaction between oltipraz and dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxybiphenyl-2,2'-dicarboxylate (DDB) after single intravenous and oral administration to rats.
Bae SK; Kim EJ; Chung SJ; Kim SG; Lee MG
J Pharm Pharmacol; 2003 Sep; 55(9):1241-9. PubMed ID: 14604467
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic changes of oltipraz after intravenous and oral administration to rats with liver cirrhosis induced by dimethylnitrosamine.
Bae SK; Lee SJ; Lee JY; Lee Y; Lee I; Kim SG; Lee MG
Int J Pharm; 2004 May; 275(1-2):227-38. PubMed ID: 15081153
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats hepatic and intestinal first-pass effects.
Kim SH; Lee MG
Life Sci; 2002 Feb; 70(11):1299-315. PubMed ID: 11883708
[TBL] [Abstract][Full Text] [Related]
14. Interspecies pharmacokinetic scaling of oltipraz in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
Bae SK; Lee SJ; Kim YG; Kim SH; Kim JW; Kim T; Lee MG
Biopharm Drug Dispos; 2005 Apr; 26(3):99-115. PubMed ID: 15723427
[TBL] [Abstract][Full Text] [Related]
15. Dose-independent pharmacokinetics of a candidate for diabetic neuropathy, SR-4668, after intravenous and oral administration to rats: Intestinal first-pass effect.
Kim EJ; Bae SK; Kim HJ; Kim YG; Kim SO; Lee DH; Lim H; Lee MG
J Pharm Sci; 2003 May; 92(5):1112-24. PubMed ID: 12712431
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of L-FMAUS, a new antiviral agent, after intravenous and oral administration to rats: contribution of gastrointestinal first-pass effect to low bioavailability.
Chung HJ; Lee JH; Woo SJ; Park HK; Koo CH; Lee MG
Biopharm Drug Dispos; 2007 May; 28(4):187-97. PubMed ID: 17377948
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect.
Kang HE; Cho YK; Jung HY; Choi KY; Sohn SI; Baek SR; Lee MG
Xenobiotica; 2009 Jun; 39(6):465-75. PubMed ID: 19480552
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and first-pass elimination of metoprolol in rats: contribution of intestinal first-pass extraction to low bioavailability of metoprolol.
Yoon IS; Choi MK; Kim JS; Shim CK; Chung SJ; Kim DD
Xenobiotica; 2011 Mar; 41(3):243-51. PubMed ID: 21128757
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin.
Bae SK; Kim JY; Yang SH; Kim JW; Kim T; Lee MG
Life Sci; 2006 Apr; 78(20):2287-94. PubMed ID: 16288785
[TBL] [Abstract][Full Text] [Related]
20. Dose-independent pharmacokinetics of a new reversible proton pump inhibitor, KR-60436, after intravenous and oral administration to rats: gastrointestinal first-pass effect.
Yu SY; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Lee MG
J Pharm Sci; 2003 Aug; 92(8):1592-603. PubMed ID: 12884246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]